These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

3083 related items for PubMed ID: 23729691

  • 21. Implantable cardioverter defibrillator therapy in paediatric practice: a single-centre UK experience with focus on subcutaneous defibrillation.
    Griksaitis MJ, Rosengarten JA, Gnanapragasam JP, Haw MP, Morgan JM.
    Europace; 2013 Apr; 15(4):523-30. PubMed ID: 23333943
    [Abstract] [Full Text] [Related]

  • 22. Appropriate use of wearable defibrillators with multiparametric evaluation to avoid unnecessary defibrillator implantation.
    Matteucci A, Pignalberi C, Di Fusco S, Aiello A, Aquilani S, Nardi F, Colivicchi F.
    Open Heart; 2024 Sep 18; 11(2):. PubMed ID: 39299735
    [Abstract] [Full Text] [Related]

  • 23. Outcomes during and after the use of the wearable cardioverter-defibrillator in a tertiary-care and a regional hospital in Switzerland.
    Kovacs B, Reek S, Saguner AM, Krasniqi N, Eriksson U, Duru F.
    Swiss Med Wkly; 2019 Nov 04; 149():w20136. PubMed ID: 31707723
    [Abstract] [Full Text] [Related]

  • 24. Early risk of mortality after coronary artery revascularization in patients with left ventricular dysfunction and potential role of the wearable cardioverter defibrillator.
    Zishiri ET, Williams S, Cronin EM, Blackstone EH, Ellis SG, Roselli EE, Smedira NG, Gillinov AM, Glad JA, Tchou PJ, Szymkiewicz SJ, Chung MK.
    Circ Arrhythm Electrophysiol; 2013 Feb 04; 6(1):117-28. PubMed ID: 23275233
    [Abstract] [Full Text] [Related]

  • 25. Wearable cardioverter-defibrillator for prevention of sudden cardiac death after infected implantable cardioverter-defibrillator removal: A cost-effectiveness evaluation.
    Healy CA, Carrillo RG.
    Heart Rhythm; 2015 Jul 04; 12(7):1565-73. PubMed ID: 25839113
    [Abstract] [Full Text] [Related]

  • 26. ECG as a risk stratification tool in patients with wearable cardioverter-defibrillator.
    Gassanov N, Mutallimov M, Caglayan E, Erdmann E, Er F.
    J Cardiol; 2022 Dec 04; 80(6):573-577. PubMed ID: 35985868
    [Abstract] [Full Text] [Related]

  • 27. Wearable cardioverter defibrillator after cardiac surgery: Analysis of real-life data from patients at transient risk of sudden cardiac death.
    Elbayomi M, Weyand M, Seitz T, Harig F.
    Ann Noninvasive Electrocardiol; 2023 Mar 04; 28(2):e13048. PubMed ID: 36723848
    [Abstract] [Full Text] [Related]

  • 28. Benefit of the Wearable Cardioverter-Defibrillator in Protecting Patients After Implantable-Cardioverter Defibrillator Explant: Results From the National Registry.
    Ellenbogen KA, Koneru JN, Sharma PS, Deshpande S, Wan C, Szymkiewicz SJ.
    JACC Clin Electrophysiol; 2017 Mar 04; 3(3):243-250. PubMed ID: 29759518
    [Abstract] [Full Text] [Related]

  • 29. Inductionless or limited shock testing is possible in most patients with implantable cardioverter- defibrillators/cardiac resynchronization therapy defibrillators: results of the multicenter ASSURE Study (Arrhythmia Single Shock Defibrillation Threshold Testing Versus Upper Limit of Vulnerability: Risk Reduction Evaluation With Implantable Cardioverter-Defibrillator Implantations).
    Day JD, Doshi RN, Belott P, Birgersdotter-Green U, Behboodikhah M, Ott P, Glatter KA, Tobias S, Frumin H, Lee BK, Merillat J, Wiener I, Wang S, Grogin H, Chun S, Patrawalla R, Crandall B, Osborn JS, Weiss JP, Lappe DL, Neuman S.
    Circulation; 2007 May 08; 115(18):2382-9. PubMed ID: 17470697
    [Abstract] [Full Text] [Related]

  • 30. Usefulness of the wearable cardioverter-defibrillator in patients at high risk for sudden cardiac death.
    Sasaki S, Tomita H, Shibutani S, Izumiyama K, Higuma T, Itoh T, Sasaki K, Horiuchi D, Kimura M, Okumura K.
    Circ J; 2014 May 08; 78(12):2987-9. PubMed ID: 25366562
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Sudden death risk in syncope: the role of the implantable cardioverter defibrillator.
    Olshansky B, Sullivan RM.
    Prog Cardiovasc Dis; 2013 May 08; 55(4):443-53. PubMed ID: 23472783
    [Abstract] [Full Text] [Related]

  • 33. Use of the Wearable Cardioverter Defibrillator in High-Risk Populations.
    Lamichhane M, Safadi A, Surapaneni P, Salehi N, Thakur RK.
    Curr Cardiol Rep; 2016 Aug 08; 18(8):78. PubMed ID: 27319008
    [Abstract] [Full Text] [Related]

  • 34. Impact of extending device longevity on the long-term costs of implantable cardioverter-defibrillator therapy: a modelling study with a 15-year time horizon.
    Boriani G, Braunschweig F, Deharo JC, Leyva F, Lubinski A, Lazzaro C.
    Europace; 2013 Oct 08; 15(10):1453-62. PubMed ID: 23696624
    [Abstract] [Full Text] [Related]

  • 35. Potential roles of the wearable cardioverter-defibrillator in acute phase care of patients at high risk of sudden cardiac death: A single-center Japanese experience.
    Sasaki S, Shoji Y, Ishida Y, Kinjo T, Tsushima Y, Seno M, Nishizaki F, Itoh T, Izumiyama K, Yokota T, Yokoyama H, Yamada M, Horiuchi D, Kimura M, Higuma T, Tomita H, Okumura K.
    J Cardiol; 2017 Jan 08; 69(1):359-363. PubMed ID: 27595899
    [Abstract] [Full Text] [Related]

  • 36. The impact of wearable cardioverter-defibrillator use on long-term decision for implantation of a cardioverter-defibrillator in a semirural acute care hospital.
    Sinha AM, Bense J, Hohenforst-Schmidt W.
    J Interv Card Electrophysiol; 2021 Nov 08; 62(2):401-407. PubMed ID: 33200285
    [Abstract] [Full Text] [Related]

  • 37. Can QRS scoring predict left ventricular scar and clinical outcomes?
    Rosengarten JA, Scott PA, Chiu OK, Shambrook JS, Curzen NP, Morgan JM.
    Europace; 2013 Jul 08; 15(7):1034-41. PubMed ID: 23493411
    [Abstract] [Full Text] [Related]

  • 38. The wearable cardioverter-defibrillator vest: Indications and ongoing questions.
    Sandhu U, Rajyaguru C, Cheung CC, Morin DP, Lee BK.
    Prog Cardiovasc Dis; 2019 Jul 08; 62(3):256-264. PubMed ID: 31077726
    [Abstract] [Full Text] [Related]

  • 39. Extended use of the wearable cardioverter-defibrillator in patients at risk for sudden cardiac death.
    Kutyifa V, Vermilye K, Daimee UA, McNitt S, Klein H, Moss AJ.
    Europace; 2018 Sep 01; 20(FI2):f225-f232. PubMed ID: 29905788
    [Abstract] [Full Text] [Related]

  • 40. Implantable cardioverter-defibrillators in hypertrophic cardiomyopathy.
    Vieira AP, Adragão PP, Santos KR, Morgado FB, Cavaco DM, Rossi R, Abecasis M, Neves JP, Bonhosrst D, Gomes JL, Gomes RS.
    Rev Port Cardiol; 2005 Mar 01; 24(3):407-15. PubMed ID: 15929624
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 155.